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ABSTRACT
Current guidelines for dialysis specify a minimum Kt/V. For
haemodialysis (HD) patients, minimum treatment time and fre-
quency is also speciﬁed. The guidelines allow for modiﬁcation
to take account of renal function. The guidelines are not specif-
ically aimed at the elderly andmay not be appropriate for all pa-
tients in this group. Increasing age is accompanied by physio-
logical and pathological changes that may modify the patient’s
response to uraemia and dialysis. Frailty and multi-morbidity
are likely, but to a variable extent. Elderly patients could be
more susceptible to the effects of uraemia and require a higher
dose of dialysis. Conversely, the generation rate of uraemic tox-
ins is lower in elderly patients, potentially reducing the need for
dialysis. In the elderly, quality of life may be more adversely af-
fected by multimorbidity than uraemic symptoms, thus the
dose of dialysis may be less relevant. Higher doses of dialysis
may be more difﬁcult to achieve in the elderly and may be less
well tolerated. We conclude that the prescription of dialysis in
the elderly should be individualized, taking multiple factors into
account. An individualized Kt/V may be useful in controlling
dialysis dose and detecting problems in delivery. However,
achievement of a speciﬁed Kt/Vmay not result in any beneﬁt to
an elderly patient and could be counterproductive.
Keywords: dialysis, dialysis adequacy, elderly, haemodialysis,
Kt/v
INTRODUCTION
Urea clearance (Kt/V) is expressed as a fraction of the body
water volume. In the Haemodialysis it is a measure of the dose
of a single dialysis session [1]. In peritoneal dialysis (PD), it in-
cludes the effect of renal function and is a measure of clearance
over a defined period, normally a week. Kt/V is one of the princi-
pal quality indicators for dialysis. Current guidelines for dialysis
all recommend ensuring that Kt/V exceeds a specified minimum
level. The guidelines do not explicitly consider the age or frailty
of the dialysis patient in setting the minimum Kt/V [2–5].
For practical purposes, in Europe, a person may be con-
sidered elderly at the age of 65 years. This originates from
‘Gesetz betreffend der Invalidita¨ts-und Altersversversicherung’,
a law enacted in 1883 by Otto von Bismarck, regulating finan-
cial support in case of incapacity and in old age, defined as be-
ginning at the age of 65 years. Since then, in many developed
countries, the age of retirement has been defined more flexibly,
taking biological functional capacity into account. In other parts
of the world, particularly in underdeveloped and developing
countries, the age of 60 years is considered the limit between
adulthood and old age. The World Health Organization defines
elderly as age 60 years, which would include the majority of
dialysis patients. Current guidelines for treatment of the elderly
disagree with the definition of ‘elderly’ or lack a definition en-
tirely [6]. Dialysis patients are usually considered as elderly
when they are>75 years old [7, 8]. For the purpose of searching
and analysing the literature, we used65 years as the definition
of elderly. This value was selected after much discussion, as a
higher age cut-off would exclude much of the literature and in-
clude a greater proportion of atypical ‘super-survivors’ with low
multimorbidity.
Frailty in dialysis patients has been defined as a combination
of exhaustion, weakness, low physical activity and weight loss
[9]. Frailty has multiple causes in addition to advancing age.
VC The Author(s) 2018. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved.
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A joint initiative of the European Renal Association
European Dialysis Transplant Association (ERA-EDTA) and
the European Union of Geriatric Medicine Societies (EUGMS)
prioritized the development of guidance on interdisciplinary re-
ferral of older patients with chronic kidney disease (CKD)
Stages 3b–5 and listed ‘the usefulness of Kt/V’ in this special
population as a topic of interest [10].
Effect of increasing dialysis dose
Variations in dialysis dose are likely to be accompanied by
advantages and disadvantages (Table 1) and the optimal dose of
dialysis will account for both. It is conceivable that the priorities
for elderly patients will differ from those of younger patients
and the optimal dose will also differ.
Haemodialysis (HD)
The current European guidelines recommend a minimum of
three dialysis sessions per week totalling at least 12 h, with a Kt/
V of at least 1.2 each session. This can be reduced if there is sig-
nificant renal function. The recommendation was based on the
findings of a reanalysis of the National Co-operative Dialysis
Study (NCDS) published in 1982 [16]. Numerous observational
studies have shown an association between Kt/V and outcome.
PD
Current guidelines recommend that the total of dialysis and
renal Kt/V should be at least 1.7 per week. This was informed
by the Adequacy of PD in Mexico (ADEMEX) study [17], one
of the very few randomized controlled trials (RCTs) designed to
investigate the effect of different Kt/Vs (it showed no benefit in
increasingKt/V to>1.7/week). Numerous observational studies
have suggested worse outcome is associated with a lower dose.
HOW AGE AND FRAILTY MAY INFLUENCE
DIALYSIS DOSE
Increasing age is accompanied by physiological and patho-
logical changes that could influence the generation of uraemic
toxins and the ease with which they may be removed by dialysis
(Table 2). These changes may influence the relationship be-
tween Kt/V and outcome and therefore the optimal dose of
dialysis.
Metabolic rate and energy expenditure fall as a function of
age in healthy individuals [18, 22]. On average, a person
80 years of age will have a reduction in energy expenditure 20%
lower than a 40-year old [18]. In theory, the rate of generation
of uraemic toxins will be reduced by a similar amount. Dialysis
Table 1. Positive and negative effects of increasing dialysis dose
Positive Negative
Physiological effects • Reduced level of uraemic toxins
• Reduced ﬂuid overload (with more frequent HD)
• Reduced ultraﬁltration rate (for nocturnal dialysis)
• Increased exposure to bio-incompatible material
• Increased solute disequilibrium (for more intensive HD)
• Loss of residual renal function (for nocturnal dialysis)
Potential, outcome,
not proven
• Improved survival
• Reduced symptoms due to reduced uraemia
• Improved nutrition
• Increased symptoms due to inﬂammation
• Increased symptoms due to disequilibrium (more intensive
dialysis)
Outcome supported
by evidence
• Improved volume management (frequent short dialysis) [11]
• Increased overall survival (frequent short dialysis) [12]
• Increased frequency of surgical/access interventions (frequent
HD) [13]
• Increased infections (frequent HD) [14]
• Increased time having treatment
• Reduced survival (frequent nocturnal dialysis) [15]
Table 2. Physiological differences between older and younger patients and their potential consequences
Differences Approximate
relative difference (%)
Consequences
Quantiﬁable physiological differences between elderly and younger patients
Reduced metabolic rate [18, 19] 20 Lower levels of uraemic toxins, potentially less need for clearance
Reduced dietary intake [20] 20
Reduced interdialytic weight gain [21] 20 Reduced need for ultraﬁltration. Potential for relatively shorter dialysis and/or
lower ultraﬁltration rate
Other differences in physiology between elderly and younger patients
Reduced cardiac function More frequent symptomatic hypotension during dialysis. More likely to termin-
ate dialysis early
More likely to have vascular disease Harder to establish ﬁstula. More likely to experience vascular steal. More fre-
quent hypotension during dialysis
Reduced mobility Logistical difﬁculties in providing dialysis
Reduced cognitive function Harder for self-care. More likely to require hospital treatment. Likely to ﬁnd
dialysis distressing
More likely to have incontinence Difﬁculties in providing longer dialysis
Increased number of chronic medical conditions Survival and quality of life limited by multimorbidity
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patients 65 years of age have25% lower salt and protein in-
take compared with younger patients [19]. Therefore, com-
pared with younger patients, the elderly would tend to have
lower serum concentrations of these toxins if clearance remains
the same. In these circumstances, dialysis dose could be reduced
in elderly patients without allowing toxin levels to rise above
those considered acceptable in younger patients.
Elderly dialysis patients tend to have lower interdialytic fluid
weight gain [21] and better compliance with sodium restric-
tions [23]. This tends to reduce the requirement for ultrafiltra-
tion, allowing either a slower ultrafiltration rate at the same
dialysis time or a shorter dialysis with the same ultrafiltration
rate compared with younger patients.
Muscle contains relatively more water, especially intracellu-
lar water, compared with other tissues. The reduction in muscle
mass, which accompanies increasing age [24], results in rela-
tively lower total body water volume [25]. In general, the pro-
portion of body water that is intracellular is lower in the elderly
compared with younger patients. Elderly persons with immo-
bility have been shown to have increased total body water com-
pared with the mobile elderly [26]. This is likely to be due to
water retention. Body water volume, as V, has a major influence
on Kt/V, regardless of the concentration of uraemic toxins.
When Kt/V is calculated using online clearance, V calculated
using anthropometric data is often used. This is likely to be
highly inaccurate in the elderly. V calculated using bioimpe-
dance may provide a better estimate [27]. During intermittent
dialysis, a rapid decrease in solute concentrations in plasma
causes a disequilibrium or difference in osmotic pressure be-
tween body compartments, which could cause headache and
other intradialytic symptoms. The magnitude of this disequilib-
rium will depend on the initial solute concentration and the Kt/
V ratio.
Elderly patients are more likely to have multimorbidity,
including heart failure, arterial disease and autonomic dysfunc-
tion. These conditions reduce the patients’ tolerance to HD
ultrafiltration and increase the risk of hypotension during HD.
Hypotension usually causes symptoms and may result in early
termination of dialysis. Repeated episodes may result in damage
to the heart and brain [28].
Older age is a risk factor for receiving a lower dialysis dose
[29]. This may be because age-associated cardiovascular disease
predisposes the patient to intradialytic hypotension, resulting in
shortened or interrupted dialysis. Similarly, cardiovascular disease
may contribute to poor vascular access, resulting in inadequate
extracorporeal blood flow or interrupted dialysis (Figure 1).
Multimorbidity, which is likely in elderly dialysis patients,
could render the patient more susceptible or sensitive to the ef-
fects of uraemia. In contrast, survival and quality of life could be
overwhelmingly limited by multimorbidity so uraemia and dia-
lysis dose could be irrelevant.
The frailty of advanced age may be associated with cognitive
dysfunction, immobility, motor dysfunction and incontinence.
These will cause logistical and practical problems in providing
adequate dialysis. The ability of the patient to become involved
in dialytic care will be reduced. The patient could be distressed
by dialysis, especially when dialysis sessions are longer, more
frequent or hospital based.
PALLIATIVE DIALYSIS
Conservative management of end-stage renal failure without
dialysis is increasingly accepted as an appropriate option for se-
lected elderly patients, especially those with severe multi-
morbidity and frailty. It makes sense for the options for such
patients to include an intermediate ‘palliative dialysis’ aimed at
controlling uraemic symptoms but not necessarily avoiding
long-term complications [30]. Such ‘palliative dialysis’ would
be designed to have lower treatment burden than standard dia-
lysis and may include twice-weekly or shorter sessions with
lower Kt/V. All available means for controlling symptoms and
maximizing physical and cognitive function would be con-
sidered to augment the effect of dialysis. These might include
non-dialysis treatments such as drugs, dietary restrictions, max-
imizing residual renal function and physical and psychological
Age
Heart and vascular disease
Shortened/interrupted sessions
Weight loss Malnutrition
Hypotension
Intradialytic symptoms
Vascular access
malfunction
Uraemia
Heart failure
Fluid overload
Anorexia
FIGURE 1: Cycle of inadequate dialysis caused by and contributing to uraemia.
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therapy in combination with dialysis. The risk that palliative
options might be used as a means of ageist rationing of dialysis
may be reduced by a rigorous patient-centred approach [31].
Twice-weekly dialysis
In observational studies, patients dialyzing twice weekly have
better preservation of renal function [32] and improved survival
[33] compared with those dialyzing with conventional thrice-
weekly dialysis regimes. These associations are likely to be due to
patient selection; patients withmore renal function are more likely
to be selected for and remain on twice-weekly dialysis. Elderly pa-
tients may have lower rates of generation of uraemic toxins and
lower fluid weight gains and thus may be better able to tolerate
twice-weekly HD. An RCT is needed to compare outcomes of
twice-weekly versus thrice-weekly dialysis in selected patients.
Incremental dialysis
Renal function is known to contribute significantly to clear-
ance during the first few years of dialysis [34]. Residual renal
function is known to have even greater effect on outcome than
dialysis dose for both HD [35] and PD [36]. The effect of renal
function on fluid balance, reducing the need for ultrafiltration,
may be particularly important.
With incremental dialysis, residual renal function is taken
into account in the prescription. Patients with significant renal
function are prescribed a shorter, less frequent and/or less in-
tense dialysis. The dialysis dose may be increased later to com-
pensate for declining renal function. The combined effect of the
renal function plus the reduced-dose dialysis should be equiva-
lent to or exceed what constitutes a full dose of dialysis in an
anuric patient.
Renal function has different effects on patients compared
with dialysis, so it is not sufficient to simply add a function of
dialysis dose (e.g. Kt/V) to a measure of renal function.
Compared with standard full-dose dialysis, patients treated by
incremental dialysis require more careful monitoring of fluid sta-
tus, nutrition and the levels of key uraemic toxins to ensure that
they are getting sufficient dialysis as renal function declines [37].
Multiple observational studies have confirmed that patients
with significant renal function has improved survival compared
with anuric patients [36], even if the dialysis dose is reduced as
part of an incremental dialysis programme [38].
A recent large observational study found that there was no
difference in survival rates between patients treated by incre-
mental versus standard HD. However, in patients with urine
volume <600mL/day or renal urea clearance <3mL/min/
1.73m2, incremental dialysis was associated with significantly
reduced survival [39].
Incremental dialysis has a lower burden of treatment. There
appears to be no adverse clinical effects during the first few
years of dialysis [40] and when there is significant renal func-
tion. The advantages of incremental dialysis might be particu-
larly important for elderly patients with short life expectancy,
where transplantation is not an option [41]. Incremental dialy-
sis is typically employed in PD. There is increasing interest
in incremental HD, particularly as a way to allow once- or
twice-weekly dialysis. An RCT is required to compare the safety
and efficacy of incremental dialysis with standard full-dose HD
in incident dialysis patients.
Intensive dialysis
It has been hypothesized that intensive dialysis will result in
better clearance of uraemic toxins and that this will result in
reduced symptoms and improved survival. Observational stud-
ies have found associations between longer, more frequent or
more intensive dialysis and improved outcome, particularly for
home treatments [42]. If dialysis time is also increased, fluid
balance is easier to achieve, with lower ultrafiltration rates.
The HEMO Study did not show improved survival in pa-
tients randomized to receive an increased dose of dialysis.
Pruritus was reduced in the high-dose group, but there were no
other significant benefits. In the Frequent Hemodialysis
Network trials, patients randomized to frequent nocturnal dialy-
sis had reduced survival compared with standard home dialysis.
Frequent short dialysis was associated with increased survival
but more numerous infections and access interventions.
A recent pro–con debate on dialysis regimens in the elderly
concluded that while there was no strong evidence to support
intensive dialysis in general, a limited trial of intensive dialysis
may be justified in more problematic patients [43].
Kt /V IS USEFUL IN THE ELDERLY: THE PRO
ARGUMENT
Malnutrition is prevalent in elderly dialysis patients [24] and has
been associated with an increased risk of death [44, 45]. Anorexia
is a known symptom of uraemia and is likely to contribute to
malnutrition. It has been hypothesized that low Kt/V could be a
risk factor for malnutrition in dialysis patients [46, 47]. While
there are likely to be multiple other potential causes of malnutri-
tion in elderly dialysis patients [48–50], low Kt/V is an easily
identifiable and potentially modifiable risk factor [51].
Multiple observational studies have shown that low Kt/V is
associated with mortality [40, 52], especially in anuric patients
[38]. This has been shown in a dialysis population with a rela-
tively high percentage of elderly patients [53]. Low Kt/V is con-
sidered a modifiable risk factor for mortality in dialysis patients
[54]. There is no evidence that elderly patients are any less sus-
ceptible to any adverse effects of low Kt/V.
The HEMO and ADEMEX RCTs have shown no benefit of
increasing Kt/V above the standard dose. This does not mean
that reducing Kt/V below the standard dose is safe or that Kt/V
is not a valuable quality measure to detect inadequate dialysis.
There is no RCT evidence showing that reducing Kt/V in anuric
patients is safe.
One of the aims of medical treatment in the elderly is to im-
prove quality of life. In a prespecified secondary analysis of the
HEMO Study, a significantly slower decline in physical health,
as expressed by the physical component summary, and a slower
worsening in bodily pain were observed in patients assigned to
an equilibrated Kt/V of 1.45 compared with a lower dialysis
dose (1.05) [55]. Although the mean age of patients in the
HEMO Study was 57.6 years, the study included a significant
number of patients65 years of age. Other studies have shown
that older people who are adequately dialyzed (Kt/V> 1.2)
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have a relatively good health-related quality of life (HRQOL)
similar to that of the general population of the same age and
gender [56] and experience a similar decline in HRQOL com-
pared with younger patients undergoing HD [57].
Kt/V can be calculated for both renal function and dialysis and
combined as a single measure. Incremental dialysis, minimizing the
negative impact on the patient by minimizing treatment time and/
or frequency yet maintaining overall adequacy, guided by measure-
ments of renal and dialysis Kt/V, has been shown to have superior
outcomes [39]. Incremental dialysis, with its reduced dose, might
potentially increase the risk of developing uraemic symptoms and
fluid overload, especially when residual renal function fails com-
pletely [39]. As a consequence, additional evidence is required to in-
form daily clinical practice. If it is implemented, incremental
dialysis would require careful control and monitoring, including
serial measurements of renal function and clearance byKt/V.
One of the aims of medical treatment in the elderly is to re-
duce symptoms. Unfortunately, many of the potentially reversible
symptoms of uraemia are difficult to distinguish from the un-
avoidable effects of ageing and age-associated multimorbidity.
Pruritus is one of the few symptoms that is relatively specific for
uraemia. Higher Kt/V has been associated with reduced pruritus
in the majority [58–60] but not all [61] of the observational stud-
ies where this was reported. This association was shown in
Dialysis Outcomes and Practice Patterns Study (DOPPS) 1 [62]
but failed to reach significance in DOPPS II.
Although urea is not particularly toxic, it has several charac-
teristics that make it suitable as a tracer to quantify dialysis.
These include free movement across the erythrocyte and tissue
cell membranes [63], stability in blood samples, relative lack of
non-renal, non-dialysis clearance and low cost of measurement.
As Kt/V is calculated from the ratios of urea concentrations in
pre- and post-HD blood, urine or dialysis fluid samples, calibra-
tion errors affecting all samples equally will not result in an
error in Kt/V. Urea-based Kt/V is the best-studied marker of
dialysis adequacy. The use of Kt/V is supported by a well-
known and studied urea kinetic model (UKM). The UKM can
be applied to all types of dialysis. Computer applications to run
the UKM are widely available and run on most computing de-
vices. The UKM can be used to calculate protein nitrogen ap-
pearance, a marker of dietary protein catabolism. The UKM can
predict Kt/V for any dialysis prescription and hence can be used
to ensure adequate dialysis and detect unaccounted for ineffi-
ciency in the dialysis process. Modern dialysis machines can now
measure Kt/V continuously and inexpensively without blood
samples using online measurements of conductivity or ultraviolet
absorbance. There is much more published evidence linking Kt/
V to outcome than any other marker of dialysis adequacy.
Although other measures of dialysis adequacy using argu-
ably more realistic uraemic toxins have been proposed [64–66],
none are as well-validated as Kt/V. Many of these alternative
methods increase complexity and cost.
Kt /V IS NOT USEFUL IN THE ELDERLY: THE
CON ARGUMENT
The use of the urea-based Kt/V has been questioned recently
[67]. The handling of urea by dialysis and the kidneys is not
typical of uraemic toxins. Compared with other toxins, urea dif-
fuses more rapidly, is reabsorbed in the renal tubules and, due
to specific channels, transfers much more readily across cell
membranes. Therefore urea is more easily cleared by dialysis
and less easily cleared by the kidneys compared with other tox-
ins. Protein-bound toxins are barely cleared by dialysis. Non-
dialysis clearance and generation rates are highly variable be-
tween patients and have relatively greater influence on the levels
of these uraemi toxins than dialysis clearance. Kt/V does not
predict levels of uraemic toxins in dialysis patients [68, 69].
The hypothesis that increasing Kt/V improves nutrition is not
supported by the evidence. Nutritional markers were not different
between standard and high-dose groups in both the ADEMEX
and HEMO studies [70]. In the Netherlands Cooperative Study on
the Adequacy of Dialysis, longitudinal observation of serum albu-
min showed a significant decrease in HD patients with the highest
Kt/V compared with lowerKt/V [71].
Calculation of the renal component of Kt/V makes assump-
tions about the renal handling of urea and creatinine, which are
known to change with advancing age [72]. Therefore Kt/V is
likely to be inaccurate in older patients.
Kt/V has been validated only in younger patients. The only RCT
in HD that has shown a significant effect of Kt/V on outcome
excluded elderly patients [16]. The changes in physiology that occur
with age are likely to influence the relationship betweenKt/V and out-
come. Few studies have specifically assessed the utility of Kt/V in eld-
erly patients.Kt/Vmayhave little or no relevance in the elderly and, in
any case, we do not knowhow to interpretKt/V in the elderly.
Much of the rationale for using Kt/V, rather than symptoms
and clinical signs, is to prevent uraemic complications from occur-
ring in the future. This may require increases in dialysis dose even
while the patient is asymptomatic. This strategy may have no
benefit for the elderly patient with a limited life expectancy.
Clearance by HD may be limited by cardiovascular disease
and access problems in elderly patients. Attempts to achieve a
specified Kt/V may involve additional access interventions and
more frequent or longer dialysis [73]. These will be disadvanta-
geous to the patient and may impair quality of life. The disad-
vantages of attempting to achieve a predefined Kt/V are likely
to outweigh the benefits.
In the elderly, quality of life will be dominated by the ‘geriat-
ric giants’: immobility, cognitive impairment, abnormalities of
gait and incontinence. These are unlikely to be affected by Kt/V.
Measuring the dose of dialysis or prescribing dialysis using Kt/V
in elderly dialysis patients may bemisleading and a distraction from
assessments that are more likely to be meaningful for the patient.
Good geriatric care is aimed at slowing the deterioration in physical
and cognitive function and in maintaining the patient’s quality of
life and independence for as long as possible. Any negative effects of
treatment on these aims should be taken into account.
ALTERNATIVE METRICS OR BIOMARKERS
FOR THE ELDERLY DIALYSIS PATIENT
Geriatric assessment
Ideally the patient should have a full geriatric assessment be-
fore starting dialysis [74]. The assessments should include
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objective tests of mobility and cognitive function as well as sub-
jective assessment of quality of life, symptoms and burden of
treatment. The assessments should be repeated periodically and
the impact of any treatment estimated.
Dialysis time
In HD, the total diffusive time or dialysis time (td) is the dur-
ation of treatment during which clearance is applied. Modern
dialysis machines automatically display elapsed td. Some of the
harmful effects of HD are due to haemoconcentration and a
decrease in blood volume associated with high ultrafiltration
rates [75]. Shorter dialysis times require higher ultrafiltration
rates. The clearance of uraemic toxin molecules, which are
larger than urea, will be influenced less by blood and dialysis
fluid flows compared with urea clearance. So the cleared volume
for uraemic toxins will be lower during a shorter dialysis, com-
pared with a longer dialysis even if Kt/V is the same. Some of
the negative impacts of dialysis are proportional to dialysis
time, including cost, inconvenience to the patient and time
away from home. Patients are more likely to prefer shorter and
less frequent dialysis [76].
There is at least as much evidence for a negative association
between primary outcomes (e.g. mortality, hospitalization and
symptoms) and td as there is for Kt/V [77]. As with Kt/V, the
evidence from RCTs that varying td can influence outcome is
mixed or lacking. There is no direct evidence to support a re-
quirement for any specific dialysis time. An RCT comparing
the effects of varying td without varying Kt/V is required to
prove an independent causative relationship between primary
outcomes and td.
Fluid status
There is more evidence for an association between fluid sta-
tus and outcome than there is for Kt/V. The significantly im-
proved survival associated with longer dialysis has been
hypothesized to be due to better control of fluid overload [78].
Fluid overload may result in symptoms and reduced cardiac
function, reducing quality of life and physical function and is
more likely in elderly dialysis patients [79]. Pulmonary oedema
may occur in the absence of fluid overload when there is im-
paired left ventricular function. Dehydration may be associated
with a loss of renal function and hypotension, which may be
symptomatic and is a potential cause of falls, a major cause of
loss of independence in the elderly. For these reasons, a compre-
hensive adequacy assessment should include an assessment of
fluid and cardiac status. This may be particularly important in
incremental dialysis, when fluid homeostasis is more critically
dependent on residual renal function. Various objective meas-
ures of fluid status are available. Bioimpedance spectroscopy
can quantify any over- or underhydration. Lung ultrasound can
detect and quantify subclinical pulmonary oedema [80].
Ultrafiltration rate
In HD, ultrafiltration rates >13mL/kg/h are associated with
reduced survival [81]. For this reason, it has been suggested that
ultrafiltration should be limited below this rate. Other studies
have not confirmed this association. It has been pointed out
that limiting ultrafiltration rates to a specified limit could result
in fluid overload unless dialysis time is increased or fluid accu-
mulation between dialysis sessions is reduced.
Concentrations of key toxins
Uraemic toxicity is generally considered to be dependent on
the concentrations of uraemic toxins, which depend on the gen-
eration rate as well as clearance. Generation rates are more
likely to be a function of body surface area than V. It is becom-
ing apparent that optimal Kt/V levels might be different for fe-
males and smaller patients [82] due to their differing
relationship between surface area and V. This may be particu-
larly true in the elderly, in whom V is hard to predict. Therefore
it has been suggested that surface area, not V, should be used to
normalize clearance in dialysis [83].
Since the generation rates may differ in elderly patients com-
pared with younger patients, it may be more valid to quantify
dialysis adequacy from the serum levels of key uraemic toxins
or surrogates rather than Kt/V. Candidate toxins might include
beta-2 microglobulin, phosphate, hydrogen ion and p-cresol
sulphate [84]. An individualized treatment might target specific
toxins that are present in particularly high concentrations or
are causing symptoms. The reduction of a specific toxin may be
achieved by non-dialysis means [85]. A high level of serum
phosphate, for example, might be better controlled by binders
and diet rather than increasing dialysis dose. Further research is
needed to link patterns of uraemic toxin levels to specific
symptoms.
Self-reported outcomes
The Standardized Outcomes in Nephrology HD initiative
has identified outcomes that are important to dialysis patients,
their caregivers and nephrologists [86]. These include multiple
self-reported outcomes. Fatigue is the first of these to be priori-
tized. The aim is to develop a core outcome measure (i.e. short
survey) for fatigue that is validated and feasible for use in all
clinical trials involving patients on HD.
CONCLUSIONS
According to both the pro and con arguments (Table 3), pro-
viding dialysis with a fixed minimum Kt/V, as specified in the
guidelines, is probably not appropriate for many elderly pa-
tients. Clinical guidelines are not intended to be applied rigor-
ously in every patient. The individual needs of the patient
should always take precedence.
Elderly and frail patients in particular require more indi-
vidualization appropriate to their clinical condition, stage of
life and priorities from their perspective. Clinical decisions
should be made jointly with an informed patient or their
representative.
According to the pro argument, measuring Kt/V has little or
no cost, especially when automatically calculated by the dialysis
machine. Although the elderly patient may not be dialyzed to a
standard, predefinedKt/V level, it may be helpful to use an indi-
vidualized Kt/V. Although the elderly patient would certainly
benefit from a full geriatric assessment as described in the con
argument, knowledge of the Kt/V could assist in achieving an
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individualized ideal dose for that patient and in helping to
troubleshoot problems with dialysis delivery.
Incremental and palliative dialysis are options that may be of
particular interest to the elderly or frail CKD patient and might
deliver a relatively low Kt/V. In these patients, a trial of
reduced-dose dialysis may be justified. Possible ways to reduce
the dose are listed in Table 4.
There is clearly a need for studies designed to determine the
factors that influence optimal dialysis dose in elderly patients.
More sophisticated measures of adequacy than Kt/V are
required.
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